Perspective Therapeutics, Inc. (CATX) SEC Filings & Earnings Calls

Clinical trial risk; no efficacy/safety data disclosed in excerpt.

“No quantitative results provided in the filing excerpt.”

Activist/strategic holder reducing position

“Lantheus Alpha sold shares on multiple days in September 2026, reducing its stake from a prior level (not specified in this amendment).”

Dilution risk

“The filing reports dilution of beneficial ownership since the original statement, indicating the issuer issued additional shares.”

Strategic investor selling pressure

“Lantheus Holdings sold 236,826 shares over four days, reducing its stake to 10.0% and authorizing further sales.”

Pre-revenue stage with increasing losses

“We have had recurring losses since inception.” · word for word

Dependence on future capital raises

“We expect we will need to raise additional capital until we are profitable, which may never occur.” · word for word

Clinical and regulatory uncertainty

“the potential that regulatory authorities may not grant or may delay approval for our product candidates” · word for word

Supply chain and tariff risk

“We are also currently evaluating how potential U.S. and international trade policies, including tariffs, might impact our costs for supplies, equipment and materials used in the development and production of our TAT drug product candidates.” · word for word

Pre-revenue stage with increasing R&D spend; no approved products.

“Net loss $26.8M; R&D $21.5M; no revenue.”

Clinical-stage company with no approved products; high dependency on trial outcomes.

“Three clinical-stage oncology programs advancing... lead program, VMT-α-NET, advancing toward a registration‑enabling study.”

Pre-revenue biotech with no approved products; high dependency on clinical trial success.

“Three clinical-stage oncology programs advancing... lead program, VMT-α-NET, advancing toward a registration‑enabling study.”

Pre-revenue stage with recurring losses

“We have had recurring losses since inception.” · word for word

Significant future expense increase expected

“Management anticipates a significant increase in expenses, particularly in research and development, as it works to implement its strategy to advance our clinical assets in their clinical trials, expand our manufacturing capabilities and progress our preclinical assets towards clinical trials.” · word for word

Dependence on clinical trial success

“We are a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body.” · word for word

Early-stage clinical data; no approved products; high risk.

“Phase 1/2a clinical trial... no approved products.”

Clinical development risk; dependency on VMT-α-NET program success and regulatory engagement.

“VMT-α-NET study on track to achieve nearly one year of follow-up in all 46 patients in Cohort 2 by mid-2026; analysis to inform patient selection strategy ongoing” · word for word

Pre-revenue clinical-stage company with widening losses and increasing cash burn

“We have had recurring losses since inception. ... Net loss $103.1M (FY2025) vs $79.3M (FY2024); cash used in operations $82.5M (FY2025) vs $18.3M (FY2024).” · word for word

IPR&D impairment indicates pipeline attrition

“we recorded a $10.0 million noncash impairment loss for the three months ended December 31, 2025, after we determined that we will no longer pursue further development of an early-stage preclinical asset within our in-process research and development portfolio.” · word for word

Significant capex commitments with execution risk

“The aggregate consideration for such equipment and services pursuant to the MESA and SOWs is approximately €49.0 million payable in cash... We currently estimate that the aggregate cost of these modifications will be approximately $27.5 million.” · word for word

Dependence on future capital raises

“We expect we will need to raise additional capital until we are profitable, which may never occur.” · word for word

Significant shareholder dilution from large equity offering

“39.6M shares and 6.6M pre-funded warrants issued”

Clinical-stage company with no approved products, high cash burn risk

“Proceeds to advance clinical development of product candidates”

Preliminary financial data subject to change; no audit performed.

“preliminary and has not been audited, reviewed or compiled” · word for word

Clinical trial risk remains; pending efficacy data for remaining patients

“Initial efficacy data pending for another 23 patients in Cohort 2 and 8 patients in Cohort 3” · word for word

Clinical-stage company with no approved products; reliance on successful clinical trials and regulatory approval.

“No revenue; net loss; cash runway into late 2026.”

Competition from other radiopharmaceutical and targeted therapy developers.

“Multiple clinical-stage programs in competitive oncology space.”

Clinical Trial Failure Risk

“We have had recurring losses since inception. We expect our expenses to increase in connection with our ongoing activities, particularly as we advance and expand preclinical activities, clinical trials and potential commercialization of our program candidates.” · word for word

Funding Risk

“We have had recurring losses since inception. We expect our expenses to increase ...” · word for word

Supply Chain Risk

“The purchase order includes a “take-or-pay” provision pursuant to which we are committed to purchasing approximately $8.4 million of thorium-228 during the term of the agreement.” · word for word

Enhanced change-in-control severance may increase cash outflow upon a qualifying event, but no immediate risk.

“if an Executive’s employment is terminated without Cause ... during a CIC Protection Period ... the Company will pay ... 12 months of salary (or, in the case of Mr. Spoor, 18 months of salary)” · word for word